Search results for "Molecular Targeted Therapy"

showing 3 items of 163 documents

Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis

2017

medicine.medical_specialtyImmunologyDisease03 medical and health sciencesPsoriatic arthritis0302 clinical medicineHumansImmunology and AllergyMedicineSpondylitis AnkylosingMolecular Targeted TherapyProtein Kinase Inhibitors030203 arthritis & rheumatologyClinical Trials as TopicTofacitinibbusiness.industrymedicine.diseaseDermatologyOncologyNilotinibAntirheumatic Agents030220 oncology & carcinogenesisApremilastbusinessAntirheumatic drugsmedicine.drugImmunotherapy
researchProduct

Therapies in early development for the treatment of opiate addiction.

2015

Opiate drugs are psychoactive substances used to manage severe pain. However, their chronic use is associated with the development of addiction. Opiate addiction represents a significant public health concern.This review focuses on the most recent advances in the pharmacological treatment of opiate addiction, from those being tested in clinical trials (Phase I and II), to preclinical studies that point to new targets. Readers will gain knowledge of the wide variety of treatments used to treat opiate addiction, including their strengths and weaknesses, and the promising pharmacological targets identified by preclinical research.Among the currently available agonist therapies, new dosage form…

medicine.medical_specialtymedia_common.quotation_subjectNarcotic AntagonistsNaltrexonePharmacological treatmentmedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPsychiatrymedia_commonPharmacologybusiness.industryAddictionGeneral MedicineOpioid-Related DisordersNaltrexoneBuprenorphineClinical trialAnalgesics OpioidDrug DesignOpiate addictionOpiatebusinessmedicine.drugMethadoneBuprenorphineExpert opinion on investigational drugs
researchProduct

Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action

2015

Dipeptidyl enoates were prepared through a high-yielding two-step synthetic route. They have a dipeptidic structure with a 4-oxoenoate moiety as a warhead with multiple reactive sites. Dipeptidyl enoates were screened against rhodesain and human cathepsins B and L, and were found to be potent and selective inhibitors of rhodesain. Among them (S,E)-ethyl 5-((S)-2-{[(benzyloxy)carbonyl]amino}-3-phenylpropanamido)-7-methyl-4-oxooct-2-enoate (6) was the most potent, with an IC50 value of 16.4 nm and kinact/Ki=1.6×106 m−1 s−1 against rhodesain. These dipeptidyl enoates display a reversible mode of inhibition at very low concentrations and an irreversible mode at higher concentrations. Inhibition…

trypanosomiasisStereochemistrysleeping sicknessCathepsin LDrug Evaluation PreclinicalChemistry Techniques SyntheticInhibition kineticsCysteine Proteinase InhibitorsBiochemistryCathepsin BInhibitory Concentration 50Structure-Activity RelationshipinhibitorsDrug DiscoveryHumansMoietyMolecular Targeted TherapyGeneral Pharmacology Toxicology and PharmaceuticsIC50Volume concentrationrhodesainPharmacologyChemistryOrganic ChemistryDual modeDipeptidesTrypanocidal AgentsCombinatorial chemistryMolecular Docking SimulationCysteine EndopeptidasesKineticsdipeptidyl enoatesTrypanosomiasis AfricanDocking (molecular)Molecular MedicineCysteine thiolateChemMedChem
researchProduct